Stock 6990 SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Equities

6990

CNE1000062J1

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:22 2024-06-20 EDT 		5-day change 1st Jan Change
175 HKD -2.62% Intraday chart for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. +3.73% +70.07%
06-18 Hong Kong Shares Fall on Weak Economic Data, Trade Tensions; Wuhan Youji Surges 27% in Trading Debut MT
06-18 Sichuan Kelun-biotech Biopharmaceutical Cancer Drug Gets Regulatory Nod; Shares Up 4% MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Hong Kong Shares Fall on Weak Economic Data, Trade Tensions; Wuhan Youji Surges 27% in Trading Debut
MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Receives Clinical Trial Notice Approving the Investigational New Drug Application for the Innovative Drug SKB518
CI
Sichuan Kelun-biotech Biopharmaceutical to Present Its Cancer Drug Phase 3 Study Results at ASCO
MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Results for Core Product Sacituzumab Tirumotecan(Sac-Tmt) At 2024 Asco Annual Meeting
CI
Sichuan Kelun-biotech Biopharmaceutical to Place 3.6 Million Shares; Inks Subscription Deal for 4.4 Million Shares
MT
Kelun-Biotech's Lung Cancer Drug Advances to Phase 2 Trials in US; Shares Up 8%
MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Key Product A400 Cleared to Start Phase 2 by the US Food and Drug Administration
CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Study Results for Core Product Scituzumab Turumotecan (SAC-TMT) at AACR Annual Meeting 2024
CI
Kelun-Biotech Shrinks Loss by 7% in 2023
MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
China Healthcare Stocks Rally on Hopes for Government Support
DJ
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Its Core Product SKB264 (MK-2870) Granted Breakthrough Therapy Designation for First-Line Treatment of Unresectable Locally Advanced, Recurring or Metastatic Pd-L1 Negative Tnbc by the National Medical Products Administration
CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Key Product A400 Granted Fast Track Designation by the US Food and Drug Administration
CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Collaboration with Merck Sharp & Dohme LLC
CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces New Drug Application for Core Product SKB264 (MK-2870) Accepts by the National Medical Products Administration
CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to Present the Updated Efficacy and Safety Results from Core Product
CI
Kelun-Biotech Biopharma Gets Filing Notice for H Share Full Circulation
MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Provides Update on Collaboration with Merck Sharp & Dohme LLC
CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Abstract for Oral Presentation of the Study Results from Core Product SKB264 (MK-2870) Published on the Website of the 2023 ESMO Congress
CI
Kelun-Biotech Invests 350 Million Yuan in Bank of Chengdu’s Structured Deposit Product
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6990 Stock
  4. News Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
  5. Highlights